ClinicalTrials.gg
RecruitingNCT05269472Updated Nov 5, 2026

Trigeminal Neuralgia Electrophysiology

An observational study in Trigeminal Neuralgia, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Minnesota · Observational

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.

Started
2022
with 4 others
Observational
8 of 34
4 open now
Primary completion
2027-11
later than 6 of 10 live
Registered
28th of 34
by date
Lead sponsor
3 of 34
University of Minnesota

Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is one of 5 that started in 2022, is one of 8 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 28th registered.

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

Browse Trigeminal Neuralgia studies →

Open to participants now

7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Trigeminal Neuralgia with a site in United States, or all of them as a file.
02

Study summary

The study intervention is to perform standard somatosensory evoked responses limited to the face during rhizotomy procedures of the gasserian ganglion (trigeminal ganglion) for the treatment of trigeminal neuralgia. The evoked responses will be measured at two locations before and after the clinical rhizotomy including: the standard contralateral scalp (EEG) and at the gasserian ganglion through an FDA-approved recording electrode.

03

Conditions studied

  • Trigeminal Neuralgia

Browse trials for

Keywords

  • Trigeminal Neuralgia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults of 18 years or older who are scheduled to undergo percutaneous rhizotomy for facial pain

Eligibility criteria

Inclusion Criteria (TGN):

  • Adults of 18 years or older
  • Scheduled to undergo percutaneous rhizotomy for facial pain

Exclusion Criteria (TGN):

  • Facial pain of unclear origin (i.e. not clearly TGN pain)
  • Rhizotomy procedure canceled

Inclusion Criteria (Healthy controls)

  • Adults of 18 years or older

Exclusion Criteria (Healthy Controls)

  • Diagnosis or history of facial pain such as TMD or TGN
  • History of migraine
  • History of any functional pain disorder: fibromyalgia, IBS, CRPS
  • Recent chronic pain (within last month)
  • Unwilling to participate for two hours in lab
  • Current acute pain
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Trigeminal Electrophysiology

    Procedure: Trigeminal Electrophysiology

  • Controls

Interventions

  • ProcedureTrigeminal Electrophysiology

    This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.

06

What researchers measure

Primary outcomes

  1. Determine the feasibility of measuring trigeminal somatosensory evoked potentials to improve personalized mapping during percutaneous rhizotomy

    percentage of consented participants who complete the study

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Nov 2027, 66 months after the start.

Of 19 observational studies under Trigeminal Neuralgia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 66 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Apr 2027 → Nov 2027 and completion Apr 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2022
First posted
Mar 8, 2022
StartActual
Apr 4, 2022
Primary completionEst.
Nov 1, 2027was Apr 2027
CompletionEst.
Nov 1, 2027was Apr 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 7, 2027→Nov 1, 2027
Nov 5, 2026
Study completion
Apr 7, 2027→Nov 1, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Apr 7, 2027→Nov 1, 2027
    Study completion Apr 7, 2027→Nov 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05269472
Responsible party
Sponsor
First posted
Mar 8, 2022
Start date
Apr 4, 2022
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Matthew Maple
Contact
maple036@umn.edu
612-946-1424
David Darrow
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion